文献速递贫血与红细胞疾病

免疫检查点抑制剂给药后再生障碍性贫血发生率与结局的真实世界证据

Real-world evidence of incidence and outcomes of aplastic anaemia following administration of immune checkpoint inhibitors.
PubMed 文献 · Br J Haematol · 2023-07-16

分析52303例接受免疫检查点抑制剂(ICI)治疗患者的电子健康记录数据库,发现77例(0.15%)再生障碍性贫血(AA),中位发生时间126天。AA最常用治疗为全身糖皮质激素60例(77.9%),32例(41.6%)在1年内恢复ICI。与倾向评分匹配的无AA患者相比,AA患者总生存期显著更差(HR 1.72,95%CI 1.19-2.50;p=0.003)。

要点

  • ICI治疗后AA发生率为0.15%(77/52303),中位发生时间126天。
  • AA最常用治疗为全身糖皮质激素60例(77.9%),32例(41.6%)1年内恢复ICI。
  • AA患者前120天总生存期陡降,匹配后OS显著更差(HR 1.72,95%CI 1.19-2.50;p=0.003)。

核心结论

  • ICI治疗后AA虽罕见(0.15%),但与匹配对照相比总生存期显著更差(HR 1.72,95%CI 1.19-2.50;p=0.003)。

研究设计与样本

  • 分析52303例接受ICI治疗患者的电子健康记录数据库,识别77例(0.15%)AA病例。

主要发现

  • AA中位发生时间为126天(四分位距58-363天)。
  • AA最常用治疗为全身糖皮质激素60例(77.9%),32例(41.6%)在1年内恢复ICI。
  • AA患者确诊后前120天总生存期陡降。
  • 与倾向评分匹配的无AA患者相比,AA患者总生存期显著更差(HR 1.72,95%CI 1.19-2.50;p=0.003)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aplastic anaemia (AA) is a rare immune-related adverse events (irAEs) after immune checkpoint inhibitors (ICIs) administration with poorly understood incidence and outcomes. We analysed an electronic health record database of 52 303 ICI-treated patients and found 77 (0.15%) cases of AA, with a median onset of 126 days (interquartile range, 58-363 days). The most used treatment for AA was systemic glucocorticoids 60 (77.9%) and 32 (41.6%) patients were able to resume ICI within 1 year. Patients diagnosed with AA had a steep decline in overall survival (OS) within the first 120 days; when compared to propensity score-matched patients without AA, they had a significantly worse OS (hazard ratio 1.72, 95% confidence interval 1.19-2.50; p = 0.003).

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dasari S, Tse W, Wang J, et al. Real-world evidence of incidence and outcomes of aplastic anaemia following administration of immune checkpoint inhibitors. Br J Haematol. 2023. PMID: 37455367. doi:10.1111/bjh.18985

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。